ID-Antigens

Significant advances in medical sciences have led to drug and chemical innovations that have yielded huge reductions in morbidity and helped increase life expectancy from ~31 years in 1900 to ~73 years in 2019. Despite this progress, infectious diseases remain a huge and growing burden. Climate change, urbanization, social inequality, migration, industrial livestock production, all these factors continue to lead to frightening increase in infectious diseases, even as growing resistance to antibiotics continue to erode the value of our existing arsenal. And while vaccines and antibody therapies demonstrate significant potential, there has been little progress in the development of vaccine and antibody therapies against microorganisms. ID-Antigens is a novel biotech firm that aims to address this challenge. We utilize advanced Mass Spectrometry(MS)-based proteomics approaches in a unique and comprehensive antigen discovery platform for unbiased exploration of mostly uncharacterized microbial proteomes, with the goal of developing vaccines and therapeutic antibodies against critical bacterial diseases. Our innovative approach has already successfully identified S protein, a promising antigen candidate for a Group A Streptococcus vaccine development (GAS, Streptococcus pyogenes). Our antigen-focused research, while initially focused on combating bacterial pathogens, has potential applicability to other pathogenic microorganism, such as viruses and fungi, as well as cancer.

网站

https://idantigens.com

ID-Antigens的外部链接

所属行业

生物技术研究

规模

2-10 人

类型

私人持股

创立

2023